Correspondence 0000950170-25-043167 from Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc.
Date: March 21, 2025 · CIK: 0001785279 · Accession: 0000950170-25-043167
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285867
Letter
Re: Metagenomi, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-285867
VIA EDGAR March 21, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky
Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Metagenomi, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to March 25, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Edwin M. O’Connor at (212) 813–8853 or Justin S. Platt at (212) 459-7340. If you have any questions regarding this request, please contact Justin S. Platt of Goodwin Procter LLP at (212) 459 7340.
Sincerely,
METAGENOMI, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR March 21, 2025 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Metagenomi, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-285867 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Metagenomi, Inc. (the “ Company ”) hereby requests that the effective date of the above-referenced registration statement (the “ Registration Statement ”) be accelerated to March 25, 2025, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Edwin M. O’Connor at (212) 813–8853 or Justin S. Platt at (212) 459-7340. If you have any questions regarding this request, please contact Justin S. Platt of Goodwin Procter LLP at (212) 459 7340. Sincerely, METAGENOMI, INC. /s/ Brian C. Thomas Brian C. Thomas Chief Executive Officer cc: Brian C. Thomas, Ph.D., Metagenomi, Inc. Matthew Wein, Metagenomi, Inc. Mitchell S. Bloom, Goodwin Procter LLP Edwin M. O’Connor, Goodwin Procter LLP Justin S. Platt, Goodwin Procter LLP